Indian pharmaceuticals group Ranbaxy Laboratories is seeking to increase its stake in its joint-venture company in Malaysia to 51%, according to its chairman, Parvinder Singh.
Dr Singh said that his company plans to venture into bigger markets and become a "research-driven player internationally," and had to increase its Malaysian interests to make these expansion plans viable. He added that his company was currently waiting for a decision from the government on the equity increase in Ranbaxy (M) Sdn Bhd to 51%.
If foreign participation can be increased, he noted, "we can look to more exports from Malaysia." Exports from Malaysia to Singapore, Vietnam and Papua New Guinea - in the form of capsules, tablets, suspensions and formulations - account for 15% of Ranbaxy Malaysia's turnover, which is forecast to reach 11 million ringgit ($4.5 million) in 1995.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze